A61P 21/04
Drugs for disorders of the muscular or neuromuscular system: for myasthenia gravis
Official title: for myasthenia gravis
A61P21/04 (Drugs for disorders of the muscular or neuromuscular system: for myasthenia gravis) appears on 4,626 US grants and 7,556 published applications in this corpus.
Search patents in A61P- Granted patents
- 4,626
- Published applications
- 7,556
- Assignees
- 1,934
- Inventors
- 11,253
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 7 | 0 |
| 1998 | 14 | 0 |
| 1999 | 20 | 0 |
| 2000 | 32 | 0 |
| 2001 | 50 | 25 |
| 2002 | 57 | 148 |
| 2003 | 83 | 279 |
| 2004 | 57 | 338 |
| 2005 | 98 | 335 |
| 2006 | 124 | 363 |
| 2007 | 151 | 372 |
| 2008 | 160 | 409 |
| 2009 | 231 | 498 |
| 2010 | 303 | 562 |
| 2011 | 278 | 465 |
| 2012 | 306 | 444 |
| 2013 | 348 | 381 |
| 2014 | 317 | 469 |
| 2015 | 314 | 335 |
| 2016 | 266 | 366 |
| 2017 | 287 | 330 |
| 2018 | 235 | 295 |
| 2019 | 200 | 277 |
| 2020 | 190 | 216 |
| 2021 | 137 | 162 |
| 2022 | 110 | 136 |
| 2023 | 77 | 101 |
| 2024 | 78 | 107 |
| 2025 | 65 | 90 |
| 2026 | 22 | 53 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-FcRn antibodies and methods for treating myasthenia gravis1 Sep 2026US 12,723,087 B2Momenta Pharmaceuticals, Inc.
- Antisense molecules and methods for treating pathologies18 Aug 2026US 12,709,749 B2The University of Western Australia
- Acetylcholinesterase inhibitor11 Aug 2026US 12,702,148 B2Taiko Pharmaceutical Co., Ltd.
- Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy16 Jun 2026US 12,653,884 B2Immunext, Inc.
- FcRn antibodies and methods of use thereof16 Jun 2026US 12,655,209 B2Momenta Pharmaceuticals, Inc.
- Fcrn antibodies and methods of use thereof8 Oct 2026US 2026/0308259 A1Momenta Pharmaceuticals, Inc.
- Tolerizing immune modifying nanoparticles for myasthenia gravis treatment24 Sep 2026US 2026/0284161 A1Cour Pharmaceuticals Development Company, Inc.
- Compositions and methods for non-surgical treatment of ptosis17 Sep 2026US 2026/0272885 A1Voom, LLC
- AAV-Mediated Gene Therapy10 Sep 2026US 2026/0263568 A1
- Fc region variant27 Aug 2026US 2026/0250360 A1Chugai Seiyaku Kabushiki Kaisha
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Polynucleotides encoding improved humanized immunoglobulins1,258US 5,693,761 AProtein Design Labs, Inc. · 1997